Covid-19 has brought Israeli life sciences companies to life, reports CTECH.
Following a record of $2.5 billion raised in 2020 (211 deals), Israeli life sciences companies have raised $900 million in the first quarter of 2021 alone, the best first quarter in the last decade, with growing interest in M&As and even a first Israeli SPAC company in this field. Just like for the Israeli hi-tech industry in general, 2021 marks the change from the initial “investment freeze” of 2020 to fast-growing fund raising and an accelerated investment period.
But life sciences also enjoyed their own perfect storm, which turned the whole sector into one of the most prominent to leverage the current boom. In Q1-Q3 2021, while 11 Israeli hi-tech companies chose SPAC mergers, raising $2.91 billion, life sciences companies raised $1.26 billion on capital markets. Read more.
